News and Events Joni Henderson 4/26/24 Joni Henderson 4/26/24 C₂N Diagnostics Expands Into Japan Through Mediford Corporation Partnership With Precivity™ Blood Testing forAlzheimer’s Disease and Brain Research Market Read More Joni Henderson 3/31/24 Joni Henderson 3/31/24 Study Finds C₂N Diagnostics’ PrecivityAD® Blood Test Provides Opportunities for Robust Cost Savings in the Evaluation of Patients with Cognitive Impairment Read More Joni Henderson 3/18/24 Joni Henderson 3/18/24 New Research Shows the PrecivityAD2™ Blood Test Has High Accuracy Compared to Amyloid PET Scans in Individuals with Cognitive Impairment Read More Joni Henderson 3/6/24 Joni Henderson 3/6/24 C₂N Diagnostics, LLC Announces Investment From Eisai Inc. Read More Joni Henderson 11/16/23 Joni Henderson 11/16/23 Researchers Identify New Cost Savings and Accuracy of C₂N Diagnostics’ Blood Tests to Enable Healthcare Providers to Better Identify Alzheimer’s Disease Read More Joni Henderson 11/7/23 Joni Henderson 11/7/23 New Research Shows High Accuracy of Precivity™ Blood Biomarkers in the Evaluation of Brain Amyloid in Pre-Clinical Alzheimer's Disease Read More Joni Henderson 10/25/23 Joni Henderson 10/25/23 C₂N Diagnostics Introduces Next-Generation Fluid Biomarker to the Field of Alzheimer’s Disease: Test to Help Researchers Track Neurofibrillary “Tau” Tangle Pathology Read More Joni Henderson 9/21/23 Joni Henderson 9/21/23 On World Alzheimer’s Day, C₂N Diagnostics’ PrecivityAD2™ Blood Test Expands Reach Read More Joni Henderson 8/17/23 Joni Henderson 8/17/23 C₂N Diagnostics Releases the PrecivityAD2™ Blood Test for Clinical Care, a Robust Assay with High Concordance to Amyloid PET and CSF Read More Joni Henderson 8/8/23 Joni Henderson 8/8/23 Real-World Evidence Shows Healthcare Providers Use C₂N Diagnostics’ PrecivityAD® Blood Test to Help Affirm Alzheimer’s Disease Diagnosis and Change Drug Treatment Decisions Read More Joni Henderson 8/2/23 Joni Henderson 8/2/23 Alzheimer’s Disease Community Benefits as C₂N Diagnostics’ Precivity™-Related Blood Biomarkers Demonstrate Robust Effectiveness, Set New Performance Standard Read More Tim West 7/11/23 Tim West 7/11/23 C₂N Diagnostics, Used in Clinical Trials for LEQEMBI™ for Alzheimer’s Disease Treatment, Is Poised to Support Medical Community in Next Steps Read More Joni Henderson 4/24/23 Joni Henderson 4/24/23 C₂N Diagnostics, Building on Recent Achievements, Bolsters Executive Team as It Prepares for Commercial Expansion Read More Joni Henderson 4/4/23 Joni Henderson 4/4/23 C₂N Diagnostics’ Precivity-Related Blood Biomarkers Shown to Improve Diagnostic Accuracy and Future Risk Prediction of Alzheimer’s Disease in Two Studies Presented at AD/PD 2023 Read More Joni Henderson 3/29/23 Joni Henderson 3/29/23 C₂N’s PrecivityAD® Blood Test, Which Identifies Amyloid Pathology as an Aid to Alzheimer’s Disease Diagnosis, Further Demonstrates Its High Accuracy in Newly Published Research Read More Joni Henderson 2/16/23 Joni Henderson 2/16/23 C₂N Diagnostics Announces Follow-on Investment from GHR Foundation as It Builds on Success in Novel Diagnostics to Aid in Alzheimer’s Disease Fight Read More Guest User 12/8/22 Guest User 12/8/22 C₂N Diagnostics’ PrecivityAD® and PrecivityAD2™ Blood Tests at CTAD 2022 Highlight the Potential and Use of Blood Biomarkers in the Diagnosis of Alzheimer’s Disease Read More Guest User 11/29/22 Guest User 11/29/22 C₂N Diagnostics Introduces the PrecivityAD2™ Blood Test Read More Guest User 11/17/22 Guest User 11/17/22 International Researchers Poised to Learn New Insights About C₂N Diagnostics’Blood Test Innovations at Clinical Trials on Alzheimer’s Disease Conference Read More Guest User 10/21/22 Guest User 10/21/22 C₂N Diagnostics Marks Two Years of PrecivityAD® Blood Test Accomplishments Read More Older Posts Subscribe to our newsletter. Sign up with your email address to receive news and updates. First Name Last Name Email Address Sign Up Thank you!
Joni Henderson 4/26/24 Joni Henderson 4/26/24 C₂N Diagnostics Expands Into Japan Through Mediford Corporation Partnership With Precivity™ Blood Testing forAlzheimer’s Disease and Brain Research Market Read More
Joni Henderson 3/31/24 Joni Henderson 3/31/24 Study Finds C₂N Diagnostics’ PrecivityAD® Blood Test Provides Opportunities for Robust Cost Savings in the Evaluation of Patients with Cognitive Impairment Read More
Joni Henderson 3/18/24 Joni Henderson 3/18/24 New Research Shows the PrecivityAD2™ Blood Test Has High Accuracy Compared to Amyloid PET Scans in Individuals with Cognitive Impairment Read More
Joni Henderson 3/6/24 Joni Henderson 3/6/24 C₂N Diagnostics, LLC Announces Investment From Eisai Inc. Read More
Joni Henderson 11/16/23 Joni Henderson 11/16/23 Researchers Identify New Cost Savings and Accuracy of C₂N Diagnostics’ Blood Tests to Enable Healthcare Providers to Better Identify Alzheimer’s Disease Read More
Joni Henderson 11/7/23 Joni Henderson 11/7/23 New Research Shows High Accuracy of Precivity™ Blood Biomarkers in the Evaluation of Brain Amyloid in Pre-Clinical Alzheimer's Disease Read More
Joni Henderson 10/25/23 Joni Henderson 10/25/23 C₂N Diagnostics Introduces Next-Generation Fluid Biomarker to the Field of Alzheimer’s Disease: Test to Help Researchers Track Neurofibrillary “Tau” Tangle Pathology Read More
Joni Henderson 9/21/23 Joni Henderson 9/21/23 On World Alzheimer’s Day, C₂N Diagnostics’ PrecivityAD2™ Blood Test Expands Reach Read More
Joni Henderson 8/17/23 Joni Henderson 8/17/23 C₂N Diagnostics Releases the PrecivityAD2™ Blood Test for Clinical Care, a Robust Assay with High Concordance to Amyloid PET and CSF Read More
Joni Henderson 8/8/23 Joni Henderson 8/8/23 Real-World Evidence Shows Healthcare Providers Use C₂N Diagnostics’ PrecivityAD® Blood Test to Help Affirm Alzheimer’s Disease Diagnosis and Change Drug Treatment Decisions Read More
Joni Henderson 8/2/23 Joni Henderson 8/2/23 Alzheimer’s Disease Community Benefits as C₂N Diagnostics’ Precivity™-Related Blood Biomarkers Demonstrate Robust Effectiveness, Set New Performance Standard Read More
Tim West 7/11/23 Tim West 7/11/23 C₂N Diagnostics, Used in Clinical Trials for LEQEMBI™ for Alzheimer’s Disease Treatment, Is Poised to Support Medical Community in Next Steps Read More
Joni Henderson 4/24/23 Joni Henderson 4/24/23 C₂N Diagnostics, Building on Recent Achievements, Bolsters Executive Team as It Prepares for Commercial Expansion Read More
Joni Henderson 4/4/23 Joni Henderson 4/4/23 C₂N Diagnostics’ Precivity-Related Blood Biomarkers Shown to Improve Diagnostic Accuracy and Future Risk Prediction of Alzheimer’s Disease in Two Studies Presented at AD/PD 2023 Read More
Joni Henderson 3/29/23 Joni Henderson 3/29/23 C₂N’s PrecivityAD® Blood Test, Which Identifies Amyloid Pathology as an Aid to Alzheimer’s Disease Diagnosis, Further Demonstrates Its High Accuracy in Newly Published Research Read More
Joni Henderson 2/16/23 Joni Henderson 2/16/23 C₂N Diagnostics Announces Follow-on Investment from GHR Foundation as It Builds on Success in Novel Diagnostics to Aid in Alzheimer’s Disease Fight Read More
Guest User 12/8/22 Guest User 12/8/22 C₂N Diagnostics’ PrecivityAD® and PrecivityAD2™ Blood Tests at CTAD 2022 Highlight the Potential and Use of Blood Biomarkers in the Diagnosis of Alzheimer’s Disease Read More
Guest User 11/29/22 Guest User 11/29/22 C₂N Diagnostics Introduces the PrecivityAD2™ Blood Test Read More
Guest User 11/17/22 Guest User 11/17/22 International Researchers Poised to Learn New Insights About C₂N Diagnostics’Blood Test Innovations at Clinical Trials on Alzheimer’s Disease Conference Read More
Guest User 10/21/22 Guest User 10/21/22 C₂N Diagnostics Marks Two Years of PrecivityAD® Blood Test Accomplishments Read More